US20210284624A1 - Immunomodulatory compounds - Google Patents

Immunomodulatory compounds Download PDF

Info

Publication number
US20210284624A1
US20210284624A1 US17/255,738 US201917255738A US2021284624A1 US 20210284624 A1 US20210284624 A1 US 20210284624A1 US 201917255738 A US201917255738 A US 201917255738A US 2021284624 A1 US2021284624 A1 US 2021284624A1
Authority
US
United States
Prior art keywords
optionally substituted
compound
group
membered
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US17/255,738
Other languages
English (en)
Inventor
Nathanael Gray
Tinghu Zhang
Eric Fischer
Alyssa Verano
Zhixiang He
Guangyan Du
Katherine Donovan
Radoslaw Nowak
Jing Ting Christine Yuan
Hu Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Priority to US17/255,738 priority Critical patent/US20210284624A1/en
Assigned to DANA-FARBER CANCER INSTITUTE, INC. reassignment DANA-FARBER CANCER INSTITUTE, INC. CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME (PAGES 1 AND 10 OF ASSIGNMENT) PREVIOUSLY RECORDED ON REEL 050071 FRAME 0526. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Assignors: YUAN, Jing Ting Christine
Publication of US20210284624A1 publication Critical patent/US20210284624A1/en
Assigned to DANA-FARBER CANCER INSTITUTE, INC. reassignment DANA-FARBER CANCER INSTITUTE, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DU, Guangyan, FISCHER, ERIC, GRAY, NATHANAEL, HE, Zhixiang, VERANO, Alyssa, ZHANG, TINGHU, DONOVAN, Katherine, NOWAK, RADOSLAW
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: DANA-FARBER CANCER INST
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
US17/255,738 2018-06-29 2019-06-27 Immunomodulatory compounds Pending US20210284624A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/255,738 US20210284624A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692176P 2018-06-29 2018-06-29
PCT/US2019/039509 WO2020006233A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds
US17/255,738 US20210284624A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Publications (1)

Publication Number Publication Date
US20210284624A1 true US20210284624A1 (en) 2021-09-16

Family

ID=68987232

Family Applications (1)

Application Number Title Priority Date Filing Date
US17/255,738 Pending US20210284624A1 (en) 2018-06-29 2019-06-27 Immunomodulatory compounds

Country Status (8)

Country Link
US (1) US20210284624A1 (zh)
EP (1) EP3814330A4 (zh)
JP (2) JP7328263B2 (zh)
KR (1) KR20210027395A (zh)
CN (1) CN113166100A (zh)
AU (1) AU2019293235A1 (zh)
CA (1) CA3102212A1 (zh)
WO (1) WO2020006233A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111278815B (zh) 2017-09-04 2024-03-08 C4医药公司 戊二酰亚胺
SG11202109024YA (en) 2019-04-12 2021-09-29 C4 Therapeutics Inc Tricyclic degraders of ikaros and aiolos
JP2023504445A (ja) * 2019-11-27 2023-02-03 キャプター セラピューティクス エス．エー． セレブロンに結合するピペリジン－２，６－ジオン誘導体、及びその使用方法
AR120773A1 (es) 2019-12-18 2022-03-16 Novartis Ag Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz
WO2022255889A1 (en) * 2021-06-01 2022-12-08 Captor Therapeutics S.A. Compounds which bind to cereblon, and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
US20190076539A1 (en) * 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
MX2018011216A (es) * 2016-03-16 2019-08-29 H Lee Moffitt Cancer Ct & Res Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
CA3050309A1 (en) * 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008007979A1 (en) * 2006-07-12 2008-01-17 Auckland Uniservices Limited (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives
US20190076539A1 (en) * 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Crew et al. CAS: 169:243035, 2018. *
Palmer et al. CAS: 148: 168597, 2008. *
Phillips et al. CAS: 168:4549, 2017, *
Yuan et al. CAS: 145:249510, 2006. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054832A1 (en) 2022-09-09 2024-03-14 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS

Also Published As

Publication number Publication date
KR20210027395A (ko) 2021-03-10
JP2023145694A (ja) 2023-10-11
EP3814330A4 (en) 2022-07-20
JP2021530453A (ja) 2021-11-11
WO2020006233A1 (en) 2020-01-02
AU2019293235A1 (en) 2020-12-17
JP7328263B2 (ja) 2023-08-16
CN113166100A (zh) 2021-07-23
CA3102212A1 (en) 2020-01-02
EP3814330A1 (en) 2021-05-05

Similar Documents

Publication Publication Date Title
US11530219B2 (en) Ligands to cereblon (CRBN)
US11542251B2 (en) IRAK degraders and uses thereof
US20230002397A1 (en) Small molecule degraders of helios and metods of use
US20210284624A1 (en) Immunomodulatory compounds
US20230158157A1 (en) Potent and selective degraders of alk
US20210277018A1 (en) New crbn modulators
US20220409731A1 (en) Degraders that target alk and therapeutic uses thereof
CA3102217A1 (en) Bispecific degraders
US20230192644A1 (en) Piperidine-2,6-diones as small molecule degraders of helios and methods of use
US20220241425A1 (en) Small molecule target bromo/acetyl proteins and uses thereof
US20240034723A1 (en) Piperidinyl small molecule degraders of helios and methods of use
US20220175722A1 (en) Degraders of fibroblast growth factor receptor 2 (fgfr2)
CA3217661A1 (en) Small molecule cyclin dependent kinase 4/6 (cdk4/6) and ikzf2 (helios) degraders and methods of use thereof
US20220033402A1 (en) Macrocyclic inhibitors of alk, trka, trkb, and ros1
US20230226196A1 (en) Compounds for targeted degradation of interleukin-2-inducible t-cell kinase and methods of use
WO2023283606A1 (en) Degraders of wild-type and mutant forms of lrrk2 and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS

Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME (PAGES 1 AND 10 OF ASSIGNMENT) PREVIOUSLY RECORDED ON REEL 050071 FRAME 0526. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNOR:YUAN, JING TING CHRISTINE;REEL/FRAME:055059/0716

Effective date: 20190715

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: DANA-FARBER CANCER INSTITUTE, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAY, NATHANAEL;ZHANG, TINGHU;FISCHER, ERIC;AND OTHERS;SIGNING DATES FROM 20190715 TO 20190718;REEL/FRAME:060323/0116

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:DANA-FARBER CANCER INST;REEL/FRAME:061660/0840

Effective date: 20210115

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER